Clinical Trials Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Oct 15, 2022; 13(10): 888-899
Published online Oct 15, 2022. doi: 10.4239/wjd.v13.i10.888
Metabonomics fingerprint of volatile organic compounds in serum and urine of pregnant women with gestational diabetes mellitus
Si-Ri-Gu-Leng Sana, Guang-Min Chen, Yang Lv, Lei Guo, En-You Li
Si-Ri-Gu-Leng Sana, Guang-Min Chen, Yang Lv, Lei Guo, En-You Li, Department of Anesthesiology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, China
Author contributions: Sana SRGL, Chen GM, Lv Y, Guo L, and Li EY designed the research study; Sana SRGL, Chen GM, Lv Y, and Guo L performed the research, and contributed new reagents and analytic tools; Sana SRGL analyzed the data and wrote the manuscript; all authors have read and approved the final manuscript.
Institutional review board statement: The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Harbin Medical University.
Clinical trial registration statement: This study is registered with the Chinese Clinical Trial Registry (No. ChiCTR2000038703).
Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at lienyou_1111@163.com.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: En-You Li, PhD, Doctor, Professor, Department of Anesthesiology, The First Affiliated Hospital of Harbin Medical University, No. 23 Youzheng Street, Nangang District, Harbin 150001, Heilongjiang Province, China. lienyou_1111@163.com
Received: June 18, 2022
Peer-review started: June 18, 2022
First decision: July 14, 2022
Revised: July 23, 2022
Accepted: September 12, 2022
Article in press: September 12, 2022
Published online: October 15, 2022
Processing time: 117 Days and 18.8 Hours
Abstract
BACKGROUND

Gestational diabetes mellitus (GDM) is a metabolic disease with an increasing annual incidence rate. Our previous observational study found that pregnant women with GDM had mild cognitive decline.

AIM

To analyze the changes in metabonomics in pregnant women with GDM and explore the mechanism of cognitive function decline.

METHODS

Thirty GDM patients and 30 healthy pregnant women were analyzed. Solid-phase microextraction gas chromatography/mass spectrometry was used to detect organic matter in plasma and urine samples. Statistical analyses were conducted using principal component analysis and partial least squares discriminant analysis.

RESULTS

Differential volatile metabolites in the serum of pregnant women with GDM included hexanal, 2-octen-1-ol, and 2-propanol. Differential volatile metabolites in the urine of these women included benzene, cyclohexanone, 1-hexanol, and phenol. Among the differential metabolites, the conversion of 2-propanol to acetone may further produce methylglyoxal. Therefore, 2-propanol may be a potential marker for serum methylglyoxal.

CONCLUSION

2-propanol may be a potential volatile marker to evaluate cognitive impairment in pregnant women with GDM.

Keywords: Gestational diabetes mellitus; Gas chromatography/mass spectrometry; Humoral biomarkers; 2-propanol

Core Tip: Gas chromatography-mass spectrometry was used in a metabonomics analysis to determine the changes in volatile metabolites in pregnant women with gestational diabetes mellitus (GDM) and to explore the mechanism of cognitive function decline in these women. 2-propanol was identified as a potential volatile marker to evaluate cognitive impairment in pregnant women with GDM.